Gliclazide tablets may produce hypoglycemia, gastrointestinal disorders, mucous membrane and skin hazards when taken for a long period of time, but not all patients with the medication will experience the above hazards. Gliclazide tablets are hypoglycemic drugs, belonging to the sulfonylurea hypoglycemic drugs, which act on pancreatic β-cells, can promote insulin secretion, improve the effect of postprandial insulin release, and then reduce blood glucose levels. Possible adverse reactions to long-term use of gliclazide are hypoglycemia, gastrointestinal disturbances (nausea, dyspepsia, diarrhea, constipation). Less commonly reported adverse reactions are mucosal and skin reactions such as rash, pruritus, and rubella, blood disorders such as anemia and thrombocytopenia, elevated liver enzyme levels, and hepatitis. Gliclazide is contraindicated in people who are allergic to gliclazide, patients with insulin-dependent diabetes mellitus, severe hepatic or renal insufficiency, breastfeeding, patients on miconazole therapy, and patients with porphyria. Gliclazide tablets should be taken under the supervision of a doctor, the occurrence of obvious adverse reactions should be promptly adjusted medication.